Moffitt Cancer Center Logo
 

Mary C. Pinder-Schenck, MD

Where You Are:

Mary C. Pinder-Schenck, MD

Medical Oncology

 
 

BOARD CERTIFICATION:
          •  Medical Oncology

FELLOWSHIP:
          •  University of Texas MD Anderson Cancer Center - Medical Oncology

RESIDENCY:
          •  University of North Carolina Hospitals - Internal Medicine

MEDICAL SCHOOL:
          •  Stanford University College of Medicine - MD

  • Gray J, Haura EB, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenk M, Kish JA, Kreahling JM, Lush RM, Neuger AM, Tetteh LF, Akar A, Zhao X, Schell MJ, Bepler G, Altiok S. A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors. Clin Cancer Res. 2014 Mar;20(6):1644-1655. Pubmedid: 24429877.

  • Byron E, Pinder-Schenck M. Systemic and targeted therapies for early-stage lung cancer. Cancer Control. 2014 Jan;21(1):21-31. Pubmedid: 24357738.

  • Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013 Jul;31(19):2404-2412. Pubmedid: 23690416. Pmcid: PMC3691357.

  • Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 2.2013. J Natl Compr Canc Netw. 2013 Jun;11(6):645-653. Pubmedid: 23744864.

  • Ettinger DS, Riely GJ, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M. Thymomas and thymic carcinomas. J Natl Compr Canc Netw. 2013 May;11(5):562-576. Pubmedid: 23667206.

  • Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KM. Non-small cell lung cancer. J Natl Compr Canc Netw. 2012 Oct;10(10):1236-1271. Pubmedid: 23054877.

  • Martins RG, D'Amico TA, Loo BW, Pinder-Schenck M, Borghaei H, Chaft JE, Ganti AK, Kong FM, Kris MG, Lennes IT, Wood DE. The Management of Patients With Stage IIIA Non-Small Cell Lung Cancer With N2 Mediastinal Node Involvement. J Natl Compr Canc Netw. 2012 May;10(5):599-613. Pubmedid: 22570291.

  • Phillips KM, Jim HS, Donovan KA, Pinder-Schenck MC, Jacobsen PB. Characteristics and correlates of sleep disturbances in cancer patients. Support Care Cancer. 2012 Feb;20(2):357-365. Pubmedid: 21311913.

  • Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007 Sep;25(25):3808-3815. Pubmedid: 17664460.

  • Pinder MC, Ibrahim NK. Nanoparticle albumin-bound paclitaxel for treatment of metastatic breast cancer. Drugs Today (Barc). 2006 Sep;42(9):599-604. Pubmedid: 17028669.

Dr. Pinder-Schenck is a medical oncologist and researcher at the H Lee Moffitt Cancer Center and Research Institute of Tampa, Florida. She specializes in the treatment of patients with lung cancer and other thoracic malignancies. Dr. Pinder-Schenck received her MD from Stanford University School of Medicine in Stanford, California She completed her internship and residency in internal medicine at the University of North Carolina in Chapel Hill, North Carolina. Dr. Pinder-Schenck then accepted a fellowship in oncology at the M.D. Anderson Cancer Center in Houston, Texas.

Dr. Pinder-Schenck has served as the principal investigator on numerous clinical trials for patients with lung cancer. She is interested in all aspects of the clinical care of patients with lung cancer. Dr. Pinder-Schenck serves on the National Comprehensive Cancer Network Lung Cancer Committee, helping to develop guidelines for the diagnosis and treatment of lung cancer. Her research focuses on identifying novel biomarkers and therapies for patients with lung cancer. She has been awarded a grant to study molecular testing in lung cancer. Dr. Pinder-Schenck has a special interest in lung cancer in women.